RealFeedApp Alamar and Nightingale Health test NULISA platform on 80,000 UK Biobank samples
Alamar Biosciences and Nightingale Health launch a project analyzing 80,000 blood samples using the NULISA platform. Funding comes from the Michael J. Fox Foundation, Alzheimer's Research UK, and LifeArc, with completion expected by the end of 2027.
- Field
- genetics and genomes
- What they did
- Researchers are developing the ultrasensitive NULISA platform to detect rare blood proteins that may signal neurodegenerative diseases.
- Why it matters
- This could identify disease signs years before symptoms appear using data from 80,000 participants.
#neurodegeneration#uk biobank#proteomics#alamar biosciences#nightingale health
